Novavax Inc. (NSDQ:NVAX) touted data today from the second Phase II trial of its RSV F nanoparticle vaccine candidate in women of child-bearing age. The research was published in the journal Vaccine.
Novavax’s nanomedicine vaccine is being developed to protect infants from the respiratory syncytial virus. The Gaithersburg, Md.-based company presented top-line data from the Phase II trial in April 2014.
Get the full story at our sister site, Drug Delivery Business News.